Q4 2024 · 13F-HR
Decheng Capital LLCholdings as filed
Filed 2025-02-14 · accession 0001104659-25-013870
$466.2M
Reported value
28
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 156944100 | CGON | CG ONCOLOGY INC | $182.7M | 39.2% | 6,371,669 | Common | SOLE |
| 67080N101 | NUVB | Nuvation Bio Inc. | $69.0M | 14.8% | 25,954,439 | Common | SOLE |
| 91678A107 | UPB | Upstream Bio Inc. | $54.0M | 11.6% | 3,285,293 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA CO NV | $19.8M | 4.24% | 770,000 | Common | SOLE |
| 452327109 | ILMN | Illumnia, Inc. | $12.7M | 2.72% | 94,767 | Common | SOLE |
| 03969F109 | RCUS | Arcus Biosciences, Inc | $12.0M | 2.58% | 808,789 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $12.0M | 2.58% | 76,772 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC(NSM) | $9.9M | 2.12% | 226,000 | Common | SOLE |
| G4444C102 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $9.3M | 1.99% | 171,600 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $8.6M | 1.84% | 167,958 | Common | SOLE |
| G10830100 | BYSI | BeyondSpring Inc. | $8.0M | 1.71% | 4,882,651 | Common | SOLE |
| N5749R100 | 2GH | MERUS NV | $8.0M | 1.71% | 189,098 | Common | SOLE |
| 55083R104 | — | Lyell Immunopharma, Inc. | $7.6M | 1.63% | 11,909,341 | Common | SOLE |
| 98943L107 | ZNTL | Zentalis Pharmaceuticals Inc. | $7.1M | 1.52% | 2,338,095 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $6.5M | 1.39% | 84,377 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $5.6M | 1.21% | 694,254 | Common | SOLE |
| 00461U105 | ACRS | Aclaris Therapeutics, Inc. | $5.6M | 1.21% | 2,266,667 | Common | SOLE |
| 52490G102 | LEGN | LEGEND BIOTECH CORP-ADR | $5.0M | 1.07% | 153,558 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $4.7M | 1.01% | 100,000 | Common | SOLE |
| 09075V102 | BNTX | Biontech SE-ADR | $4.6M | 0.98% | 40,000 | Common | SOLE |
| 05153U107 | AURA | Aura Biosciences, Inc. | $4.2M | 0.91% | 515,555 | Common | SOLE |
| 29446K106 | EQ | Equillium Inc. | $3.3M | 0.71% | 4,447,308 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $2.2M | 0.48% | 400,000 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $2.1M | 0.45% | 49,767 | Common | SOLE |
| 04963C209 | ATRC | AtriCure Inc. | $818,916 | 0.18% | 26,797 | Common | SOLE |
| 747324101 | PYXS | Pyxis Oncology, Inc (formerly Apexigen) | $509,824 | 0.11% | 326,810 | Common | SOLE |
| 384747101 | GRAL | GRAIL INC | $172,859 | 0.04% | 9,684 | Common | SOLE |
| 67080N119 | NUVB/WS | Nuvation Bio Inc. | $148,593 | 0.03% | 646,057 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.